KRYS — Krystal Biotech, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1711279 ·
Last close
$298.55
Market Cap
$8.85B
52W High
$382.54
52W Low
$202.99
ADV30
291,674
Next earnings
2026-11-02

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 127,341,000 119,785,000 71,145,000 63,068,000 1,586,056,000 462,841,000 150,472,000
Jun 2026 119,222,000 112,785,000 58,417,000 54,768,000 1,500,648,000 427,740,000 141,522,000
Mar 2026 116,357,000 110,034,000 53,689,000 55,932,000 1,396,967,000 501,313,000 120,238,000
Dec 2025 107,105,000 100,513,000 44,270,000 51,400,000 1,333,794,000 496,304,000 114,234,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$323,928,000
Investing CF
$-271,988,000
Financing CF
$23,673,000
CapEx
$-13,848,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$7.37
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$197,931,000
Inventory
$50,787,000
Receivables
$133,115,000
ST Investments
$449,010,000
EBIT TTM
$227,521,000
Pretax Income TTM
$258,797,000
Interest Exp TTM
—
Analysts
9

Yahoo Snapshot (yfinance, live)

Total Revenue
$470,024,992
EBITDA
$229,034,000
Free Cash Flow
$221,590,880
Enterprise Value
$8,012,855,808
Total Cash
$911,851,008
Total Debt
$8,588,000
Shares Out
29,633,472
Trailing EPS
$7.36
Book Value
$48.45
ROE
17.5%
ROA
10.1%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 389,130,000 161,295,000 204,831,000 1,333,794,000 114,234,000 1,219,560,000 200,865,000
Dec 2024 290,515,000 103,248,000 89,159,000 1,055,838,000 109,458,000 946,380,000 123,420,000
Dec 2023 50,699,000 -97,117,000 10,932,000 818,355,000 39,714,000 778,641,000 -88,804,000
Dec 2022 0 -120,196,000 -139,975,000 558,450,000 36,219,000 522,231,000 -100,569,000

TTM Snapshot

Revenues TTM
$440,484,000
NetIncome TTM
$241,465,000
OpCashFlow TTM
—
Assets (Latest)
$1,500,648,000
Forward EPS
$9.23

Max Pain — expiry 2027-03-19

max pain strike: $300.00 · spot: $317.66 · call oi: 445 · put oi: 917

Peers — same industry

TickerNameMarket CapLastDaily %
PCVX Vaxcyte, Inc. $9.40B $59.40 —
QGEN QIAGEN N.V. $10.27B $49.75 —
RGEN REPLIGEN CORP $10.30B $162.18 —
KYMR Kymera Therapeutics, Inc. $10.37B $121.52 —
TWST Twist Bioscience Corp $7.43B $112.00 —

News headlines (Yahoo Finance, 1h cache)

Krystal Biotech to Present at Upcoming Investor Conferences
2026-11-10 13:00 · Yahoo
Krystal Biotech (KRYS) Stock Stays Above Fair Value After Buyback Plan
2026-11-03 06:11 · Yahoo
Earnings Beat May Change The Case For Krystal Biotech (KRYS) Stock
2026-11-03 05:10 · Yahoo
Is Krystal Biotech (KRYS) Undervalued On Earnings, Buybacks, And Vyjuvek Growth?
2026-11-03 02:16 · Yahoo
Krystal Biotech Sinks 11% Despite Q3 Beat as Eye Trial Enrollment “Progressed Slower Than Initially Anticipated”
2026-11-03 00:51 · Yahoo
Krystal Biotech Inc (KRYS) (Q3 2026) Earnings Call Highlights: Vyjuvek Revenue Jumps 30% to ...
2026-11-02 23:03 · Yahoo
Krystal Biotech, Inc. Q3 2026 Earnings Call Summary
2026-11-02 17:57 · Yahoo
Krystal Biotech (KRYS) Q3 2026 Earnings Call Transcript
2026-11-02 16:58 · Yahoo
Krystal Biotech Q3 Earnings Call Highlights
2026-11-02 16:14 · Yahoo
Krystal Biotech, Inc. (KRYS) Surpasses Q3 Earnings and Revenue Estimates
2026-11-02 15:20 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.